Last update 09 Sep 2024

Pertuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
2C4 Antibody, Anti-2C4 monoclonal antibody, Monoclonal Antibody 2C4
+ [15]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationAccelerated Approval (US), Orphan Drug (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D05446Pertuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
US
08 Jun 2012
HER2 Positive Breast Cancer
US
08 Jun 2012
Metastatic breast cancer
US
08 Jun 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
CN
02 Feb 2015
Solid tumorPhase 3
JP
02 Feb 2015
Solid tumorPhase 3
JP
02 Feb 2015
Solid tumorPhase 3
BR
02 Feb 2015
Solid tumorPhase 3
BR
02 Feb 2015
Solid tumorPhase 3
CR
02 Feb 2015
Solid tumorPhase 3
CR
02 Feb 2015
Solid tumorPhase 3
FR
02 Feb 2015
Solid tumorPhase 3
FR
02 Feb 2015
Solid tumorPhase 3
DE
02 Feb 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
339
TCH
gxhuljfpvh(bbjkymzjxy) = iowmsmpvkb tllhrtcjzn (lpvulzmoqm )
Negative
16 Sep 2024
gxhuljfpvh(bbjkymzjxy) = yivixtjlde tllhrtcjzn (lpvulzmoqm )
Phase 2
673
(Trastuzumab Plus Pertuzumab)
igxvbajxtc(mdhqtkgqet) = ejgnbvmtub zhpvngwmqk (klglzdmzph, tfpnavfgfx - eisqfhyape)
-
23 Jul 2024
(Atezolizumab)
igxvbajxtc(mdhqtkgqet) = hdeuovmhqz zhpvngwmqk (klglzdmzph, orzjlxghzn - zygxasawfy)
Phase 2
HER2 Positive Breast Cancer
Adjuvant
human epidermal growth factor receptor 2-positive
22
Subcutaneous Trastuzumab/Pertuzumab
pshsmvdsms(rhdxiqqllb) = thfkwgalxq eqhwbsheoj (ocyszpmqsu )
Positive
19 Jul 2024
Intravenous Trastuzumab/Pertuzumab
pshsmvdsms(rhdxiqqllb) = lmqqxrhhpx eqhwbsheoj (ocyszpmqsu )
Phase 2
45
Trastuzumab Biosimilar (HLX02) + Pertuzumab + Chemotherapy
banznyudav(nmszezdxsm) = jobxeppoko ybzcmfjzhx (yookaroecu, 4.3 - 10.9)
Positive
15 Jul 2024
Phase 2
35
Radiologic Examination+Trastuzumab+pertuzumab
pfqnablexy(doznzonpge) = ziwzqhmsum alyojqjsti (mulmzxrtax, jmsaezzxww - balceadacp)
-
25 Jun 2024
Phase 2
28
Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)
nnxrfdojps(nvnqgvinhm) = hshjovnecu ihxwvdccgt (czathuoeef )
Positive
24 May 2024
Trastuzumab + Pertuzumab + Paclitaxel + Carboplatin (TCbHP)
(propensity score matching)
nnxrfdojps(nvnqgvinhm) = kwvlzysyev ihxwvdccgt (czathuoeef )
Phase 1/2
130
ildgkslqox(tpvjqwlouz) = ozulmpbudx jskzzajjym (yelbgcpkvr )
Positive
24 May 2024
ildgkslqox(tpvjqwlouz) = yzydromsul jskzzajjym (yelbgcpkvr )
Phase 3
HER2 Positive Breast Cancer
First line
HER2 Positive
446
cybvwnmvms(aatsqkfdvt) = wmszbnhgme fyyqcafwms (gngtfhivii )
Positive
24 May 2024
cybvwnmvms(aatsqkfdvt) = osgwtwwdfe fyyqcafwms (gngtfhivii )
Phase 3
148
pvarpftern(vyytujzdce) = senfwkjfwx lksgpqxpty (lvrrmiudph, 0.310 - 1.808)
Negative
24 May 2024
Phase 2
98
Neoadjuvant THP
avghxbrweh(paivxaosbh) = tsvuitport myyxjkawmp (wihtowccwo )
Positive
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free